Pharmacokinetics in geriatric psychiatry

Kristin L. Bigos, Marci L. Chew, Robert Bies

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalCurrent Psychiatry Reports
Volume10
Issue number1
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Geriatric Psychiatry
Pharmacokinetics
Psychiatry
Pharmaceutical Preparations
Aptitude
Neurology
Population
Kidney
Drug Therapy
Liver

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Pharmacokinetics in geriatric psychiatry. / Bigos, Kristin L.; Chew, Marci L.; Bies, Robert.

In: Current Psychiatry Reports, Vol. 10, No. 1, 02.2008, p. 30-36.

Research output: Contribution to journalArticle

Bigos, Kristin L. ; Chew, Marci L. ; Bies, Robert. / Pharmacokinetics in geriatric psychiatry. In: Current Psychiatry Reports. 2008 ; Vol. 10, No. 1. pp. 30-36.
@article{f1dfe522363747b694fa2df4ec57a2e1,
title = "Pharmacokinetics in geriatric psychiatry",
abstract = "Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite.",
author = "Bigos, {Kristin L.} and Chew, {Marci L.} and Robert Bies",
year = "2008",
month = "2",
doi = "10.1007/s11920-008-0007-4",
language = "English (US)",
volume = "10",
pages = "30--36",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics in geriatric psychiatry

AU - Bigos, Kristin L.

AU - Chew, Marci L.

AU - Bies, Robert

PY - 2008/2

Y1 - 2008/2

N2 - Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite.

AB - Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite.

UR - http://www.scopus.com/inward/record.url?scp=39449130457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449130457&partnerID=8YFLogxK

U2 - 10.1007/s11920-008-0007-4

DO - 10.1007/s11920-008-0007-4

M3 - Article

C2 - 18269892

AN - SCOPUS:39449130457

VL - 10

SP - 30

EP - 36

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

SN - 1523-3812

IS - 1

ER -